# ZEO SCIENTIFIX, INC (ZEOX) · Edgar & Edgarette company card

> Zeo Scientifix (ZEOX) grew revenue 12.5% in FY2025 to $5 million, operating margin -104% against a -15.8% median for biological products, (no diagnostic substances), equity -93.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1557376 · fiscal year ended 2025-10-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ZEOX) · [JSON](https://www.pops4.com/boards/company/ZEOX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5M |
| Revenue growth, 1 year | 12.5% |
| Revenue growth per year | -1.8% |
| Operating margin | -103.6% (prior year -115.1%) |
| Net margin | -106.2% |
| Operating cash flow | −$718,000 |
| Capital spending | $23,000 |
| Free cash flow | −$741,000 |
| Cash | $221,000 |
| Long-term debt | — |
| Total assets | $2M |
| Total equity | −$1M |
| Equity ÷ assets | -93.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -177.04 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -103.6% in FY2025; revenue is hard to predict: its 80% range is ±58%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $5.2M (FY2025). Experience: revenue up 12.5% on the year, down 1.8% a year over 4 years; operating margin -103.6%, up from -115.1%. Soundness: equity -93.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.7M and $10.2M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.5M to $11.2M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -103.6% against a -15.8% median; growth 12.5% against 21.4%.

Range logged 2026-09-24, receipt f56b74c9e2f68c46, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-09-28 ([filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626010483/0001829126-26-010483-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-09-14 ([filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626010084/0001829126-26-010084-index.htm))
- Item 5.02 Director or officer change: 6, latest 2026-06-12 ([filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626006446/0001829126-26-006446-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626011913/0001829126-26-011913-index.htm)
- 8-K · filed 2026-10-30 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626011800/0001829126-26-011800-index.htm)
- 8-K · filed 2026-10-26 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626011497/0001829126-26-011497-index.htm)
- 8-K · filed 2026-09-15 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year · [filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626010114/0001829126-26-010114-index.htm)
- 8-K · filed 2026-09-15 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626010100/0001829126-26-010100-index.htm)
- 8-K · filed 2026-09-01 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557376/000182912626009583/0001829126-26-009583-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001557376.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1557376

## Cite

POPS4, Edgar & Edgarette: ZEO SCIENTIFIX, INC (ZEOX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ZEOX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.